Charles River Laboratories International, Inc. (CRL) Investor Relations Documents

Charles River Laboratories International, Inc. (CRL) investor relations documents from the company's IR site: 3 presentations, 21 press releases; latest deck 2026-08-05. Read in-app with summaries. First-party data.

Charles River Laboratories Q2 2026 Earnings Presentation: Charles River Laboratories 2Q 2026 results show 0.1% organic revenue growth and $3.02 non-GAAP EPS, exceeding prior outlooks amid improving biopharma demand.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-05Press releaseCharles River Laboratories Announces Second-Quarter 2026 Results
2026-08-05Earnings deckCharles River Laboratories Q2 2026 Earnings Presentation
2026-07-15Press releaseCharles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call
2026-07-13Press releaseCharles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment
2026-06-18Press releaseCharles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise
2026-06-02PresentationCharles River Laboratories at the William Blair 46th Annual Growth Stock Conference Presentation
2026-06-01Press releaseCharles River Laboratories to Present at William Blair and Jefferies Conferences
2026-05-13Press releaseCharles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
2026-05-11Press releaseCharles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow
2026-05-07Press releaseCharles River Laboratories Announces First-Quarter 2026 Results
2026-04-30Press releaseCharles River Launches Rat In Vitro Fertility Services Demonstrating Embryology Capabilities
2026-04-21Press releaseCharles River Highlights Effectiveness of VCGs in Toxicology
2026-04-16Press releaseCharles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call
2026-04-09Press releaseCharles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association
2026-03-26ESG report2025 ESG Data Table (PDF)
2026-03-02Press releaseCharles River Laboratories to Present at TD Cowen and Barclays Conferences
2026-02-25Press releaseCharles River Laboratories Provides Update on Planned Divestitures
2026-02-18Press releaseCharles River Laboratories Announces Executive Appointments
2026-02-18Press releaseCharles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance
2026-01-21Press releaseCharles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call
2026-01-21Press releaseCharles River Enters Manufacturing Collaboration with Gazi University
2026-01-12Press releaseCharles River Laboratories Provides Business Updates
2026-01-08Press releaseCharles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan
2023-09-21Presentation08-RMS-2023-Investor-Day-Presentation_FINAL.pdf
2022-04-07ESG reportCharles River Laboratories Publishes 2021 Corporate Citizenship Report
Press releaseCharles River Laboratories Adds Nancy C. Andrews, M.D., Ph.D., to Board of Directors

CRL overview · CRL earnings · CRL financials · CRL KPIs · CRL documents · CRL ownership · CRL peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.